ADMA Biologics Reports Year End 2016 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
273
ADMA Biologics Reports Year End 2016 Financial Results, Accomplishments and Upcoming Milestones

RAMSEY, N.J., Feb. 24, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA ), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases, today announced its financial results for the year ended December 31, 2016.

“During the recently completed fiscal year and into 2017, we have achieved significant progress towards transforming ADMA Biologics into a fully vertically integrated manufacturer and provider of commercial hyperimmune globulins and other plasma derived biological products,” stated Adam Grossman, President and Chief Executive Officer.  “Since signing the definitive purchase agreement with Biotest to acquire certain manufacturing and therapy-related business unit assets in January 2017, we have been working aggressively on integration efforts and advancing toward the closing of this transformational transaction, which is anticipated to occur during the first half of 2017.”

Mr. Grossman continued, “We are also pleased with our continued year-over-year revenue growth from our plasma collection business segment.  We believe this segment will serve as a strong foundation and supply resource for a portion of the raw material normal source plasma and specialty hyperimmune plasma used for our anticipated, near-term commercial production in our vertically integrated platform post-closing.

“Additionally, we continue to work on parallel paths collaborating with Biotest on remediation efforts to address the Complete Response Letter (“CRL”) for our lead product candidate RI-002, Biotest’s outstanding inspection issues and the Warning Letter, while we work on transition services arrangements and the total integration of the to-be acquired assets on a post-closing basis,” Mr. Grossman concluded.

2016 Accomplishments

  • The U.S. Food and Drug Administration (the “FDA”) Indicated that no Additional Clinical Trials were Required in Order to Seek Approval of RI-002 for its Intended Indication in Patients with Primary Immune Deficiency Disease (“PIDD”) 
  • Achieved Approximately 50% Year-Over-Year Revenue Growth From Plasma Centers
  • Presented Positive Data on Lead Product Candidate RI-002 at Multiple Medical Conferences
  • Completed an Equity and Debt Financing to Enhance and Strengthen the Cash Position

2017 Anticipated Goals and Milestones

  • Consummate and Close Biotest Therapy Business Unit (“BTBU”) Acquisition
  • Successfully Integrate BTBU Operations into ADMA Biologics
  • Generate Accretive Revenues From FDA-Approved BTBU Acquired Assets
  • Progress Warning Letter and Inspection Issues Remediation Efforts and Work to Establish a Timeline with the FDA for Such Remediation
  • Progress Resubmission of Biologics License Application for RI-002
  • Initiate Buildout of Additional ADMA BioCenters Plasma Collection Operations
  • Initiate New Specialty Plasma Collection Programs at ADMA BioCenters

Financial Results for the Year Ended 2016

At December 31, 2016, ADMA had cash, cash equivalents and short-term investments of $15.3 million, as compared to $16.8 million at December 31, 2015.  The consolidated net loss for the year ended December 31, 2016 was $19.5 million, or $(1.61) per share, as compared to a consolidated net loss of $18.0 million, or ($1.73) per share, for the year ended December 31, 2015.  ADMA reported revenues of $10.7 million for the year ended December 31, 2016 compared to $7.2 million for the year ended December 31, 2015, which represents 49% growth year-over-year.  This growth was primarily driven by revenues generated from increased donor plasma collections from our plasma centers, in particular from our recently approved Marietta, Georgia, plasma center, which received FDA approval in the third quarter of 2015, as well as stronger “spot-market” pricing.  The year-over-year increase in net loss of $1.5 million is primarily attributable to increased cost of product revenue directly related to increased sales of normal source plasma, increased general and administrative expenses of $1.7 million associated with fees incurred for the proposed acquisition of the BTBU consisting of fees paid for legal, accounting and due diligence advisors.  Also contributing to the increase in net loss were costs associated with consulting services provided to us related to pre-launch, commercial planning, and market research, as well as increased plasma centers expenses of $0.8 million which were primarily a result of increased plasma collections at our Marietta, Georgia plasma center, and increased research and development expenses of $0.7 million attributable to increased validation, testing and production costs for RI-002 and an increase in regulatory consulting and legal fees.  Total other expense decreased approximately $0.3 million, to $2.2 million for the year ended December 31, 2016, compared to $2.5 million for the year ended December 31, 2015.  The decrease in other expense is primarily attributable to a loss on extinguishment of debt of $0.7 million, which was recorded in the second quarter of 2015 for the refinancing of an existing loan with our new lender, Oxford Finance LLC., offset by increased interest expense of $0.4 million as a result of increased debt in 2016 as compared to 2015.  Included in the net loss for the year ended December 31, 2016, were non-cash expenses of $1.3 million for stock-based compensation and $0.5 million for depreciation and amortization.   

About ADMA Biologics, Inc.  (ADMA)

ADMA is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the proposed treatment of Primary Immune Deficiency Disease (PIDD) and the prevention and treatment of certain infectious diseases. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons.  ADMA has received U.S. Patent 9,107,906 relating to certain aspects of its product candidate.  For more information, please visit www.admabiologics.com .

Forward-Looking Statements This press release contains "forward-looking statements" pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "intend," "target,” “will," “is likely,” "would," "may," or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements include, but are not limited to, statements concerning our ability to develop, manufacture, and commercialize specialty plasma-based biologics for the proposed treatment of immune deficiencies and the prevention of certain infectious diseases, the success of our work with our third party vendors and the U.S. Food and Drug Administration in furtherance of and progress towards an approval of our Biologics License Application for specialty plasma-based biologics and the ability of such third parties to respond adequately or in a timely manner to the issues raised by the FDA, our ability to successfully pursue commercialization and prelaunch activities, the timeframe within which we may receive approval from the FDA for specialty plasma-based biologics, if at all, the potential of our specialty plasma-based biologics to provide meaningful clinical improvement for patients living with PIDD or other indications and our ability to realize increased prices for plasma growth in the plasma collection industry. These forward-looking statements also involve risks and uncertainties concerning our ability to complete and close the proposed transaction described herein, the expected closing date of such transaction, the anticipated benefits and synergies of such transaction, anticipated future combined businesses, operations, products and services, and liquidity, debt repayment and capital return expectations.  Actual events or results may differ materially from those described in this document due to a number of important factors. These factors include, among others, the outcome of regulatory reviews of the proposed transaction; the ability of the parties to complete the transaction; the ability of ADMA to successfully integrate the to-be acquired therapy business, operations (including manufacturing and supply operations), sales and distribution channels, business and financial systems and infrastructures, research and development, technologies, products, services and employees; the ability of the parties to retain their customers and suppliers; the ability of the parties to minimize the diversion of their managements’ attention from ongoing business matters; ADMA’s ability to manage the increased scale, complexity and globalization of its business, operations and employee base post-closing, among others.  Forward-looking statements are subject to many risks and uncertainties that could cause our actual results and the timing of certain events to differ materially from any future results expressed or implied by the forward-looking statements , including those risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto. Therefore, current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation or warranty by ADMA or any other person that the objectives and plans of ADMA will be achieved in any specified time frame, if at all. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements.

ADMA BIOLOGICS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
Years Ended December 31, 2016 and 2015
 
             
    2016       2015  
       
REVENUES:      
Product revenue $   10,518,203     $   7,050,283  
License and other revenue     142,834         127,350  
Total Revenues     10,661,037         7,177,633  
       
OPERATING EXPENSES:      
Cost of product revenue     6,360,761         4,311,461  
Research and development     7,688,238         7,015,946  
Plasma centers     5,447,691         4,618,065  
General and administrative     8,494,742         6,745,968  
       
TOTAL OPERATING EXPENSES     27,991,432         22,691,440  
       
LOSS FROM OPERATIONS     (17,330,395 )       (15,513,807 )
       
OTHER INCOME (EXPENSE):      
Interest income     50,317         37,830  
Interest expense     (2,239,569 )       (1,842,716 )
Other income     4,496         -   
Change in fair value of stock warrants     -               67,860  
Loss on extinguishment of debt     -          (719,097 )
OTHER EXPENSE, NET     (2,184,756 )       (2,456,123 )
       
NET LOSS $   (19,515,151 )   $   (17,969,930 )
       
NET LOSS PER COMMON SHARE,      
Basic and Diluted $   (1.61 )   $   (1.73 )
       
WEIGHTED AVERAGE SHARES OUTSTANDING, Basic and Diluted       12,153,407       10,412,305  
       
CONDENSED CONSOLIDATED BALANCE SHEET INFORMATION:
 
  *December 31, 2016   *December 31, 2015
Assets      
Cash, cash equivalents and short-term investments                   $   15,305,051      $   16,809,136   
Total Assets $   23,685,085     $   23,714,517  
       
Accumulated deficit $ (106,934,818 )   $   (87,419,667 )
Total Stockholders’ (Deficiency) Equity $   (4,457,262 )   $   820,974  
       
*Condensed from audited financial statements

 

CONTACT: Brian Lenz Vice President and Chief Financial Officer | 201-478-5552 | www.admabiologics.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 210

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 42

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 290

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 343

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 203

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 135

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 212

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 129

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 169

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Target Kyverna Therapeutics: Key Details You Need

Updated Category News Views 136

Understanding Ongoing Investigations at Kyverna Therapeutics As the financial landscape continues to evolve, investors find themselves keenly interested in the developments surrounding Kyverna Therapeutics, Inc. (NASDAQ: KYTX). With a prominent law firm engaged in scrutinizing potential claims, the situation promises vital updates for concerned stakeholders. Faruqi &...

Continue Reading
Moody's Upgrades Phillips Edison to Baa2 Rating with Stability

Updated Category News Views 131

Moody's Upgrades Phillips Edison to Baa2 Rating CINCINNATI — Phillips Edison & Company, Inc. (Nasdaq: PECO), a prominent operator of high-quality grocery-anchored neighborhood shopping centers, has recently received an upgrade from Moody's Ratings. The company's issuer credit rating has been raised from 'Baa3' to 'Baa2', reflecting its strong operational performance and...

Continue Reading
Quantum Stocks Soar Amid Rumored Federal Investments

Updated Category News Views 222

Quantum Computing Stocks on the Rise Shares of IonQ Inc. (NYSE: IONQ), Rigetti Computing (NASDAQ: RGTI), and D-Wave Quantum (NYSE: QBTS) have experienced remarkable increases in pre-market trading. IonQ rose by 13.71%, Rigetti by 11.67%, and D-Wave surged by an impressive 15.90%. This surge comes as there are reports suggesting the federal government may be considering...

Continue Reading
Unlocking Success: How a One-Hour Morning Routine Can Transform Lives

Updated Category News Views 384

The Transformative Power of a Screen-Free Morning Jeff Bezos, the visionary behind Amazon, emphasizes the importance of a structured morning without distractions. His approach encourages starting the day without diving into screens, allowing for a calm and focused beginning. Understanding Bezos' Morning Ritual Instead of beginning his day with devices, Bezos opts for...

Continue Reading
Nokia's Strategic Moves: Infinera Acquisition and Stock Insights

Updated Category News Views 186

Nokia's Evolution in Telecom and Network Solutions Nokia Oyj is a global leader in telecom equipment and offers comprehensive network infrastructure solutions. While it once dominated the mobile phone market, Nokia has since repositioned itself as an essential player in the deployment and support of 5G and 4G networks. Its main competitor, Telefonaktiebolaget LM Ericsson,...

Continue Reading